The NIH is awarding researchers $18.8 million to help support global research into concussions and TBI.
The NIH has launched three innovative projects which will focus on the development of therapeutics for nicotine addiction, AMD and Fragile X Syndrome.
A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer’s disease in aged mice following short-term treatment.
Researchers implanted pacemaker electrodes into the medial forebrain bundle of patients suffering from major depression and performed deep brain stimulation. In a matter of days, in six out of seven patients, symptoms such as anxiety, despondence, listlessness and joylessness had improved considerably.
Infants at 7 months of age who go on to develop autism are slower to reorient their gaze and attention from one object to another when compared to 7-month-olds who do not develop autism, and this behavioral pattern is in part explained by atypical brain circuits.
Buphenyl (sodium phenylbutyrate), a medication approved for the treatment of hyperammonemia, could help prevent the progression of Alzheimer’s disease, a new study finds.
A new study identifies a potential treatment window of several years for plaques in the brain considered to cause memory loss in diseases such as Alzheimer’s.
Researchers find that, compared with neurotypical children, those with autism have multiple redundant connections between neighboring brain areas at the expense of long-distance links.
Researchers discover a three molecule complex could be a target for treating Huntington’s Disease, a genetic and currently incurable brain disease which causes movement disorders and dementia.
Using a sugar-coated scaffold, researchers move closer to unlocking the therapeutic use of stem cells to treat a wide range of diseases from Alzheimer’s to diabetes.